Abstract
Psoriasis is a common dermatosis, affecting from 1 to 3 percent of the population. Until recently, the mainstays of topical therapy have been corticosteroids, tars, anthralins and keratolytics. Recently, however, vitamin D analogs, a new anthralin preparation and topical retinoids have expanded physicians' therapeutic armamentarium. These new topical therapies offer increased hope and convenience to the large patient population with psoriasis.
MeSH terms
-
Administration, Cutaneous
-
Administration, Topical
-
Anthralin / therapeutic use
-
Anti-Inflammatory Agents / therapeutic use
-
Calcitriol / analogs & derivatives
-
Calcitriol / therapeutic use
-
Coal Tar / therapeutic use
-
Dermatologic Agents / administration & dosage
-
Dermatologic Agents / adverse effects
-
Dermatologic Agents / therapeutic use*
-
Humans
-
Keratolytic Agents / therapeutic use
-
Nicotinic Acids / therapeutic use
-
Patient Education as Topic
-
Psoriasis / drug therapy*
-
Retinoids / therapeutic use
-
Teaching Materials
-
Vitamin D / analogs & derivatives
-
Vitamin D / therapeutic use
Substances
-
Anti-Inflammatory Agents
-
Dermatologic Agents
-
Keratolytic Agents
-
Nicotinic Acids
-
Retinoids
-
Vitamin D
-
calcipotriene
-
Coal Tar
-
tazarotene
-
Calcitriol
-
Anthralin